Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.

Maxim GrymonprezTine L De BackerStephane SteurbautKoen BousseryLies Lahousse

Published in: Cardiovascular drugs and therapy (2021)

The benefit-risk profile of NOACs seems preserved in (morbidly) obese AF patients and patients with low body weight. However, more data are needed on underweight AF patients (BMI < 18.5 kg/m2) and on differences between NOACs in these patients.

Keyphrases

end stage renal disease
body weight
ejection fraction
newly diagnosed
chronic kidney disease
atrial fibrillation
peritoneal dialysis
metabolic syndrome
prognostic factors
bariatric surgery
adipose tissue
weight loss
venous thromboembolism
big data
artificial intelligence
weight gain